134 related articles for article (PubMed ID: 18297428)
1. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
Wasielewski M; Hanifi-Moghaddam P; Hollestelle A; Merajver SD; van den Ouweland A; Klijn JG; Ethier SP; Schutte M
Breast Cancer Res Treat; 2009 Jan; 113(2):285-91. PubMed ID: 18297428
[TBL] [Abstract][Full Text] [Related]
2. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
[TBL] [Abstract][Full Text] [Related]
3. Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations.
Hollestelle A; Elstrodt F; Timmermans M; Sieuwerts AM; Klijn JG; Foekens JA; den Bakker MA; Schutte M
Breast Cancer Res Treat; 2010 Jul; 122(1):125-33. PubMed ID: 19763817
[TBL] [Abstract][Full Text] [Related]
4. The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis.
Koppert LB; Schutte M; Abbou M; Tilanus HW; Dinjens WN
Br J Cancer; 2004 Feb; 90(4):888-91. PubMed ID: 14970869
[TBL] [Abstract][Full Text] [Related]
5. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of hBUB1, human mitotic checkpoint gene in multiple carcinomas.
Mimori K; Inoue H; Alder H; Ueo H; Tanaka Y; Mori M
Oncol Rep; 2001; 8(1):39-42. PubMed ID: 11115566
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of breast cancer associated with CHEK2*1100delC.
Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
[TBL] [Abstract][Full Text] [Related]
8. Mutations truncating the EP300 acetylase in human cancers.
Gayther SA; Batley SJ; Linger L; Bannister A; Thorpe K; Chin SF; Daigo Y; Russell P; Wilson A; Sowter HM; Delhanty JD; Ponder BA; Kouzarides T; Caldas C
Nat Genet; 2000 Mar; 24(3):300-3. PubMed ID: 10700188
[TBL] [Abstract][Full Text] [Related]
9. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
[TBL] [Abstract][Full Text] [Related]
10. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
[TBL] [Abstract][Full Text] [Related]
11. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers.
Williams LH; Choong D; Johnson SA; Campbell IG
Clin Cancer Res; 2006 Dec; 12(23):6967-72. PubMed ID: 17145815
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CHEK2 mutations in prostate cancer.
Wu X; Dong X; Liu W; Chen J
Hum Mutat; 2006 Aug; 27(8):742-7. PubMed ID: 16835864
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
[TBL] [Abstract][Full Text] [Related]
15. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
[TBL] [Abstract][Full Text] [Related]
16. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
[TBL] [Abstract][Full Text] [Related]
17. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
18. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
[TBL] [Abstract][Full Text] [Related]
19. Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals.
Jekimovs CR; Chen X; Arnold J; Gatei M; Richard DJ; Spurdle AB; Khanna KK; Chenevix-Trench G;
Br J Cancer; 2005 Feb; 92(4):784-90. PubMed ID: 15700044
[TBL] [Abstract][Full Text] [Related]
20. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
